Literature DB >> 18385901

Hormone abuse in sports: the antidoping perspective.

Osquel Barroso1, Irene Mazzoni, Olivier Rabin.   

Abstract

Since ancient times, unethical athletes have attempted to gain an unfair competitive advantage through the use of doping substances. A list of doping substances and methods banned in sports is published yearly by the World Anti-Doping Agency (WADA). A substance or method might be included in the List if it fulfills at least two of the following criteria: enhances sports performance; represents a risk to the athlete's health; or violates the spirit of sports. This list, constantly updated to reflect new developments in the pharmaceutical industry as well as doping trends, enumerates the drug types and methods prohibited in and out of competition. Among the substances included are steroidal and peptide hormones and their modulators, stimulants, glucocorticosteroids, beta2-agonists, diuretics and masking agents, narcotics, and cannabinoids. Blood doping, tampering, infusions, and gene doping are examples of prohibited methods indicated on the List. From all these, hormones constitute by far the highest number of adverse analytical findings reported by antidoping laboratories. Although to date most are due to anabolic steroids, the advent of molecular biology techniques has made recombinant peptide hormones readily available. These substances are gradually changing the landscape of doping trends. Peptide hormones like erythropoietin (EPO), human growth hormone (hGH), insulin, and insulin-like growth factor I (IGF-I) are presumed to be widely abused for performance enhancement. Furthermore, as there is a paucity of techniques suitable for their detection, peptide hormones are all the more attractive to dishonest athletes. This article will overview the use of hormones as doping substances in sports, focusing mainly on peptide hormones as they represent a pressing challenge to the current fight against doping. Hormones and hormones modulators being developed by the pharmaceutical industry, which could emerge as new doping substances, are also discussed. 2008, Asian Journal of Andrology, SIMM and SJTU. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18385901     DOI: 10.1111/j.1745-7262.2008.00402.x

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  12 in total

Review 1.  Androgens and doping tests: genetic variation and pit-falls.

Authors:  Anders Rane; Lena Ekström
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

Review 2.  The abuse of diuretics as performance-enhancing drugs and masking agents in sport doping: pharmacology, toxicology and analysis.

Authors:  Amy B Cadwallader; Xavier de la Torre; Alessandra Tieri; Francesco Botrè
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

3.  Effects of muscular strength training and growth hormone (GH) supplementation on femoral bone tissue: analysis by Raman spectroscopy, dual-energy X-ray absorptiometry, and mechanical resistance.

Authors:  Robson Chacon Castoldi; Guilherme Akio Tamura Ozaki; Thiago Alves Garcia; Ines Cristina Giometti; Tatiana Emy Koike; Regina Celi Trindade Camargo; João Domingos Augusto Dos Santos Pereira; Carlos José Leopoldo Constantino; Mário Jefferson Quirino Louzada; José Carlos Silva Camargo Filho; William Dias Belangero
Journal:  Lasers Med Sci       Date:  2019-06-15       Impact factor: 3.161

Review 4.  The androgen receptor and its use in biological assays: looking toward effect-based testing and its applications.

Authors:  Amy B Cadwallader; Carol S Lim; Douglas E Rollins; Francesco Botrè
Journal:  J Anal Toxicol       Date:  2011-11       Impact factor: 3.367

5.  Concentration and Preservation of Very Low Abundance Biomarkers in Urine, such as Human Growth Hormone (hGH), by Cibacron Blue F3G-A Loaded Hydrogel Particles.

Authors:  Claudia Fredolini; Francesco Meani; K Alex Reeder; Sally Rucker; Alexis Patanarut; Palma J Botterell; Barney Bishop; Caterina Longo; Virginia Espina; Emanuel F Petricoin; Lance A Liotta; Alessandra Luchini
Journal:  Nano Res       Date:  2008-12       Impact factor: 8.897

6.  Novel serum biomarkers for erythropoietin use in humans: a proteomic approach.

Authors:  Britt Christensen; Lucila Sackmann-Sala; Diana Cruz-Topete; Jens Otto L Jørgensen; Niels Jessen; Carsten Lundby; John J Kopchick
Journal:  J Appl Physiol (1985)       Date:  2010-10-21

Review 7.  Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects.

Authors:  Lindsey J Anderson; Jamie M Tamayose; Jose M Garcia
Journal:  Mol Cell Endocrinol       Date:  2017-06-09       Impact factor: 4.102

8.  Erythropoietin update 2011.

Authors:  Mariusz Kowalczyk; Maciej Banach; Dimitri P Mikhailidis; Jacek Rysz
Journal:  Med Sci Monit       Date:  2011-11

Review 9.  In vitro androgen bioassays as a detection method for designer androgens.

Authors:  Elliot R Cooper; Kristine C Y McGrath; Alison K Heather
Journal:  Sensors (Basel)       Date:  2013-02-06       Impact factor: 3.576

10.  Gamma-Aminobutyric Acid Increases Erythropoietin by Activation of Citrate Cycle and Stimulation of Hypoxia-Inducible Factors Expression in Rats.

Authors:  Keun-Tae Park; Jong-Kwon Han; Seong Jin Kim; Young-Hee Lim
Journal:  Biomolecules       Date:  2020-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.